Search
Clinical trial phase IIa of the first APA inhibitor (QGC001) as central acting antihypertensive agent and development of new "Best in Class"APA inhibitors – CLINAPAI
Hypertension (HTN) remains still difficult to control: In France, only 50% of the hypertensive population is at the blood pressure (BP) target, more than 25% of the hypertensive patients more than 3 antihypertensive treatments and 10% of the hypertensive patients are resistant to at least 3 antihype
Rational optimization of an innovative survivin therapeutic synthetic vaccine for treatment of cancers – OPTIVAX
Tumors often escape and even exploit the immune system to promote their survival, expansion and metastatization. However, tumor-specific T-cells retain the potential to effectively control and even eradicate large tumors, which led to the design of immunotherapeutic cancer vaccines. These have been
Cell/extracellular matrix interactions: application to skin repair – SKINHEALING
Attempts to promote epithelialisation in skin healing appear to be beneficial in acute wounds because accelerating wound closure will shorten the overall wound healing process and reduce the risk of infection. It also opens challenging perspectives in chronics wounds by offering strategies to favour
Medication of a new concept on depression – MEDINCOD
The aim of the project is the development of a new treatment for depression. Depression is a disease particularly frequent which can reach to 20% of the population in the industrial countries. The numerous origins of this pathology involving multiple genes as well as environmental and developmental
Cancer stem-cell therapy with anti-ganglioside humanized monoclonal antibodies – GANGSTEMAB
Based on experimental evidence, scientists have proposed that tumors may possess cells similar in phenotype to normal stem cells and that these cancer stem cells (CSCs) are the origin of tumors. Cancer stem cells (CSCs) theory supposes the existence of some highly tumorigenic cells with the properti
Gla-domainless Factor Xa as a new treatment of hemorrhages – MINITEN
Our goal is to provide a therapeutic solution for two unmet medical needs that are the hemophilia with inhibitors (both A and B) and the overdosing of DOA or the bleeding following a trauma under DOA. This project called MiniTen is based on the use of a gamma-carboxylated deleted factor X. This mole
Optimising CNS-targeted neurotensin-peptide-vector conjugates for induction of therapeutic hypothermia – VEC2Brain
Central Nervous System (CNS) diseases are the world’s leading cause of disability. The brain's blood vessels possess unique anatomical and physiological features - collectively known as the blood-brain barrier (BBB) - that substantially limit the delivery of drugs to the nervous tissue. Strategies f
Development of innovative assays for the discovery of GPCRs biased signaling ligands – RSignal
Our project aims at developing and validating tools allowing the detection of active forms of various GPCR effectors. These tools will be used to develop assays compatible with HTS. Such assays are avaited in the pharma industry to validate new biased ligands identified in HTS campaings. 3 types o
Prerequisite for therapeutic management of sequels from AbdomiNo-pelvic radioTHrapy by local injection of MSC combined with a hydrOgel and an HS-mimetic – ANTHOS
Radiotherapy is still an indisputable component of the management of malignant pelvic diseases. It represents an optimal compromise between control of the tumour and damage to healthy tissue surrounding the tumour, i.e. risk/benefit. Irradiation of healthy areas can cause loss of intestinal integrit
Toward an alternative anticancer therapeutic strategy targeting the Hedgehog pathway using the dependence receptor paradigm – DepR-SHH
Dependence receptors (DRs) are transmembrane receptors which trigger apoptosis in the absence of their ligands. They have been shown to act as conditional tumor suppressors (Mazelin et al., Nature, 2004; Mehlen and Puisieux, Nat Rev. Cancer, 2006; Mehlen et al., Nat Rev. Cancer, 2011, Castets et al.
Neoglycoenzyme for lysosomal disease therapy – LysoProd
LysoProd project concerns the establishment of an experimental prototype for the production of a functionalized enzyme drug that can be transferred to an industrial level for the treatment of Pompe disease, a rare lysosomal storage disease. Studies and patents obtained by our academic teams UMR5247
Use of fucoidan as a diagnostic and therapeutic ligand of intravascular thrombi in cardiovascular pathology – FucoThrombo
Thrombotic events remain one of the main causes of mortality and morbidity in western countries, involving both the arterial and the venous part of the circulation: myocardial infarction, ischemic stroke, aneurysms, peripheral arterial disease, atrial thrombus and embolisms, phlebothrombosis and pul